Sat, Apr 19, 2014, 10:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • hokiestock hokiestock Jul 23, 2013 11:04 AM Flag

    Arry

    I suggest taking a look at ARRY and Transition Therapeutics, they will diverse your portfolio some in depression, astma. I also like ASTX in the long haul and CRIS.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I would think they will raise more cash very soon, and that is not a bad thing, as they continue to search for a partner on the asthma drug. When that is announced, that is the time to pounce. IMO

      What do you think?

      • 2 Replies to raysfrom98
      • Their pipeline is much deeper than the asthma drug, I stated this last week they remind me a lot of INCY. I think it is one of the better 5 dollar stocks around could quickly run to over a billion in market cap. I like Transition as well they have couple of interesting small molecues and low float. Biotech has changed a little over the last year or so these companies are getting more recognition and sleepers like TSRX and ARRY do not hang around for ever. I am afraid all of these cancer agents are going to kill each other in the long run but I do not view CLDX in that boat over 50% of drugs in research are in oncology. That is why Asthma, Pain and Joint, Mental Illness are so huge and that is why Regeneron is over 200 because of the cholesterol agents in research.

      • You have that right Ray,
        I always like to double up, when a offering is announced, and the fools sell their stock.
        There is a nice piece of change to be made on the recovery after the offering is completed.

 
CLDX
14.24-0.45(-3.06%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.